Minireviews
Copyright ©The Author(s) 2016.
World J Gastrointest Oncol. Oct 15, 2016; 8(10): 745-750
Published online Oct 15, 2016. doi: 10.4251/wjgo.v8.i10.745
Table 2 Response rate, time to progression and survival in patients with advanced
Ref.nPatient characteristicsProtocolsOSRR/TTP
Kim et al[32]292003-200831% Cis + Gem 69% Cis + 5-FU12.5 mo (no significant difference between the two groups)NC
Shoji et al[33]261997-20105-FU-based gemcitabine-based 5-FU based gemcitabine-basedOS = 9.1 mo 8 mo 12.3 moRR = 7.7%